OncLive

Most Recent

Precision Medicine Picks up Pace Across Oncology

September 28th 2020

By Caroline Seymour

Andre Goy, MD, MS, discusses how matching the right treatment with the right patient resides at the heart of precision medicine, but with continued interest in pursuing the molecular milieu of cancers, precision medicine has the potential to better inform pre- and post-cancer interventions as well.

Precision Medicine Challenges Deepen in DLBCL As Subtypes Emerge

September 28th 2020

By Rachel Narozniak, MA

Despite efforts to advance the precision oncology portfolio for patients with diffuse large B-cell lymphoma by categorizing subtypes of the molecularly heterogenous disease, developing treatment routes for these alternate forms presents an uphill battle.

The Role of Chemoimmunotherapy Dwindles Among New Regimens in Frontline CLL

September 28th 2020

By Jessica Hergert

Although frontline chemoimmunotherapy regimens have been the gold standard for patients with chronic lymphocytic leukemia for many years, the advent of BTK inhibitors and other novel drugs has moved the field toward adopting chemotherapy-free options for patients in this setting.

FDA Approval Insights: Fixed-Dose Pertuzumab/Trastuzumab in HER2+ Breast Cancer

September 28th 2020

By OncLive Staff

In our exclusive interview, Antoinette R. Tan, MD, of Atrium Health, discusses the FDA approval of the fixed-dose combination of pertuzumab and trastuzumab in HER2-positive breast cancer and highlights the results of the pivotal FeDeriCa trial.

Injectable Sintilimab/Bevacizumab Biosimilar Combo Improves Survival in Frontline HCC

September 28th 2020

By Kristi Rosa

Frontline sintilimab injection in combination with bevacizumab biosimilar injection resulted in a statistically significant improvement in progression-free survival and overall survival compared with sorafenib in patients with advanced hepatocellular carcinoma.

Latest Videos

All Content

x